Ryvu Therapeutics SA (RVU) AI Stock Analysis

• Market Cap: zł639.27M
• Dividend Yield: N/A
• Average Volume (3M): 26.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 15.45%
• EPS Growth: -25.81%
• Country: PL
• Employees: 328
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.07
• Shares Outstanding: 23,120,148
• 10 Day Avg. Volume: 24,770
• 30 Day Avg. Volume: 26,695
• PEG Ratio: -0.40
• Price to Book (P/B): 6.19
• Price to Sales (P/S): 11.42
• P/FCF Ratio: -6.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: zł25.00 ▼(-9.58% Downside)

The overall stock score is primarily impacted by weak financial performance and technical analysis. The company's negative profitability and cash flow issues, combined with bearish technical indicators, contribute to a low score. The lack of positive valuation metrics further exacerbates the stock's unattractiveness.

Ryvu Therapeutics SA Business Overview & Revenue Model

Company Description

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

How the Company Makes Money

Ryvu Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company earns money through various streams including milestone payments from partnerships with larger pharmaceutical companies, licensing agreements, and potential royalties from product sales once drugs are commercialized. Additionally, Ryvu may receive funding through grants or subsidies aimed at supporting innovative research in oncology. Strategic collaborations with other biotech and pharmaceutical firms can also enhance its financial position, providing both upfront payments and shared development costs.

Ryvu Therapeutics SA Financial Statement Overview

Summary

Ryvu Therapeutics SA shows revenue growth but faces significant profitability and cash flow challenges. The moderate leverage is offset by negative return on equity and ongoing net losses, indicating financial instability.

Income Statement

Ryvu Therapeutics SA shows a positive revenue growth rate of 22.56% in the latest year, indicating potential growth. However, the company faces significant challenges with negative net profit margins and EBIT margins, reflecting ongoing profitability issues. The gross profit margin is relatively strong at 74.89%, but the overall financial health is impacted by substantial net losses.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.52, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is not explicitly calculated, but the balance sheet shows a decrease in stockholders' equity, which could be a concern for financial stability.

Cash Flow

Ryvu Therapeutics SA exhibits a positive free cash flow growth rate of 8.31%, but the operating cash flow remains negative, which is concerning. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings, but overall cash flow health is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	69.80M	77.97M	46.86M	38.80M	11.19M	15.41M
Gross Profit	13.38M	58.39M	29.31M	21.40M	-2.54M	6.65M
EBITDA	-100.04M	-96.83M	-81.04M	-65.21M	-65.96M	-17.87M
Net Income	-118.69M	-111.44M	-92.11M	-83.78M	-79.08M	-31.69M
Balance Sheet
Total Assets	255.34M	378.78M	403.20M	474.98M	228.81M	295.64M
Cash, Cash Equivalents and Short-Term Investments	130.69M	225.40M	233.67M	102.44M	88.23M	161.19M
Total Debt	70.54M	75.51M	906.00K	2.77M	5.07M	7.41M
Total Liabilities	184.12M	234.89M	143.61M	131.59M	59.39M	71.92M
Stockholders Equity	71.22M	143.88M	259.59M	343.39M	161.30M	223.72M
Cash Flow
Free Cash Flow	-116.36M	-135.38M	-88.11M	12.03M	-69.85M	-44.82M
Operating Cash Flow	-113.94M	-129.48M	-84.55M	21.32M	-57.87M	-10.64M
Investing Cash Flow	27.32M	137.16M	-195.54M	690.00K	8.06M	-55.94M
Financing Cash Flow	-619.00K	94.21M	240.83M	-2.46M	-3.17M	130.69M

Ryvu Therapeutics SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 27.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:RVU, the sentiment is Positive. The current price of 27.65 is above the 20-day moving average (MA) of 26.27, above the 50-day MA of 25.98, and below the 200-day MA of 28.66, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 61.90 is Neutral, neither overbought nor oversold. The STOCH value of 93.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PL:RVU.

Ryvu Therapeutics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLV	59 Neutral	zł853.53M	-295.80	-1.25%	―	14.10%	-99.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAB	46 Neutral	zł133.18M	-2.25	-59.73%	―	-74.16%	-192.42%
CTX	44 Neutral	zł464.41M	-11.37	-109.96%	―	-40.45%	27.53%
RVU	38 Underperform	zł639.27M	-5.39	-95.69%	―	15.45%	-25.81%